Hem/Onc Round-up: COVID-19 and Cancer Treatment, How to Reduce Colorectal Cancer Mortality, and more

Here are the top stories recently covered by DocWire News in the hematology/oncology section. In this edition, read about the COVID-19 pandemic’s effect on radiotherapy treatment, how to reduce colorectal cancer mortality, the effects of delayed surgery in very early breast cancer patients, characteristics and treatment of radiation-induced alopecia in patients with certain cancers, and more.

A study explored how the COVID-19 pandemic impacted cancer patients who underwent radiotherapy at a single institution in Wuhan, China.

A new white paper laid out by the American Gastroenterological Association outlines how fewer people would die of colorectal cancer if health care providers adopted a new model of screening.

The COVID-19 pandemic has led to cancelled surgeries, delayed treatments, and patients hesitating to seek care. For patients with ductal carcinoma in situ breast cancer, delaying surgery may not impact their overall survival, according to a study.

Researchers characterized persistent radiation-induced alopecia in patients with primary central nervous system tumors or head and neck sarcomas and provided treatment options.

A study assessed the correlation between the human papillomavirus (HPV) vaccination and high-grade cervical intraepithelial neoplasia (CIN) and found that the HPV vaccine was correlated with a reduced risk of high-grade CIN.

Childhood cancer survivors with severe hearing loss are at a significant increased risk of neurocognitive deficits, according to a study.

Non-white are a disproportionately higher risk gastric cancer compared to non-Hispanic white Americans, and this was especially true among Asian Americans.

Black children with cancer may be less likely to undergo proton radiotherapy, according to a study. The analysis observed a correlation between race and proton radiotherapy treatment, while neighborhood poverty level did not appear to be a significant factor.

Chemotherapy is not commonly used in treating patients with localized soft tissue sarcoma, according to a study.